Latest period
$9.19B
YoY change
+47.3%
5Y CAGR
-1.6%
Peak year (2016)
$29.88B
Latest annual
$8.66B
Total Equity history chart for Amgen (AMGN) from 1985 to 2025
Latest: $8.66B
Total Equity growth chart for Amgen (AMGN) from 1985 to 2025
Latest: +47.3%
Total Equity history table for Amgen (AMGN) from 1985 to 2025
| 2025 | $8.66B | +47.3% | +$2.78B | ||
| 2024 | $5.88B | -5.7% | −$355.00M | ||
| 2023 | $6.23B | +70.2% | +$2.57B | ||
| 2022 | $3.66B | -45.4% | −$3.04B | ||
| 2021 | $6.70B | -28.8% | −$2.71B | ||
| 2020 | $9.41B | -2.7% | −$264.00M | ||
| 2019 | $9.67B | -22.6% | −$2.83B | ||
| 2018 | $12.50B | -50.5% | −$12.74B | ||
| 2017 | $25.24B | -15.5% | −$4.63B | ||
| 2016 | $29.88B | +6.4% | +$1.79B | ||
| 2015 | $28.08B | +8.9% | +$2.31B | ||
| 2014 | $25.78B | +16.7% | +$3.68B | ||
| 2013 | $22.10B | +15.9% | +$3.04B | ||
| 2012 | $19.06B | +0.2% | +$31.00M | ||
| 2011 | $19.03B | -20.5% | −$4.92B | ||
| 2010 | $23.94B | +5.6% | +$1.28B | ||
| 2009 | $22.67B | +11.2% | +$2.28B | ||
| 2008 | $20.39B | +14.1% | +$2.52B | ||
| 2007 | $17.87B | -5.8% | −$1.09B | ||
| 2006 | $18.96B | -7.3% | −$1.49B | ||
| 2005 | $20.45B | +3.8% | +$746.00M | ||
| 2004 | $19.70B | +1.6% | +$315.90M | ||
| 2003 | $19.39B | +6.0% | +$1.10B | ||
| 2002 | $18.29B | +250.5% | +$13.07B | ||
| 2001 | $5.22B | +20.9% | +$902.70M | ||
| 2000 | $4.31B | +42.7% | +$1.29B | ||
| 1999 | $3.02B | +18.0% | +$461.30M | ||
| 1998 | $2.56B | +19.8% | +$422.90M | ||
| 1997 | $2.14B | +12.2% | +$233.00M | ||
| 1996 | $1.91B | +14.0% | +$234.50M | ||
| 1995 | $1.67B | +31.2% | +$397.50M | ||
| 1994 | $1.27B | +8.7% | +$102.30M | ||
| 1993 | $1.17B | +25.5% | +$238.30M | ||
| 1992 | $933.70M | +75.8% | +$402.60M | ||
| 1991 | $531.10M | +33.4% | +$133.10M | ||
| 1990 | $398.00M | — | — | ||
| 1988 | $161.90M | -1.0% | −$1.60M | ||
| 1987 | $163.50M | +94.6% | +$79.50M | ||
| 1986 | $84.00M | +4.2% | +$3.40M | ||
| 1985 | $80.60M | — | — |
- 2025$8.66B+47.3%
- 2024$5.88B-5.7%
- 2023$6.23B+70.2%
- 2022$3.66B-45.4%
- 2021$6.70B-28.8%
- 2020$9.41B-2.7%
- 2019$9.67B-22.6%
- 2018$12.50B-50.5%
- 2017$25.24B-15.5%
- 2016$29.88B+6.4%
- 2015$28.08B+8.9%
- 2014$25.78B+16.7%
- 2013$22.10B+15.9%
- 2012$19.06B+0.2%
- 2011$19.03B-20.5%
- 2010$23.94B+5.6%
- 2009$22.67B+11.2%
- 2008$20.39B+14.1%
- 2007$17.87B-5.8%
- 2006$18.96B-7.3%
- 2005$20.45B+3.8%
- 2004$19.70B+1.6%
- 2003$19.39B+6.0%
- 2002$18.29B+250.5%
- 2001$5.22B+20.9%
- 2000$4.31B+42.7%
- 1999$3.02B+18.0%
- 1998$2.56B+19.8%
- 1997$2.14B+12.2%
- 1996$1.91B+14.0%
- 1995$1.67B+31.2%
- 1994$1.27B+8.7%
- 1993$1.17B+25.5%
- 1992$933.70M+75.8%
- 1991$531.10M+33.4%
- 1990$398.00M—
- 1988$161.90M-1.0%
- 1987$163.50M+94.6%
- 1986$84.00M+4.2%
- 1985$80.60M—
Total Equity values are taken from Amgen's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Amgen (AMGN)
According to Amgen's latest reported financial statements, the company's latest reported total equity is $9.19B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Amgen (AMGN) reported total equity of $8.66B – surged 47.3% year-over-year.
Amgen total equity has contracted on net over the period, with a -1.6% compound annual growth rate over 2020–2025 (5 years).
Amgen total equity plunged from $29.88B in 2016 to $8.66B in 2025, a 71.0% drawdown.
The record annual total equity stands at $29.88B, reached in 2016; the historical low of $80.60M was recorded in 1985.
Amgen Total Equity by Year
Amgen Total Equity 2025: $8.66B
2025's total equity for Amgen came in at $8.66B, surged 47.3% from 2024.
Amgen Total Equity 2024: $5.88B
Amgen posted total equity of $5.88B in 2024, declined 5.7% below 2023.
Amgen Total Equity 2023: $6.23B
In 2023, Amgen reported total equity of $6.23B, surged 70.2% from 2022.
Amgen Total Equity 2022: $3.66B
Amgen total equity in 2022 was $3.66B, plunged 45.4% below 2021.
Amgen Total Equity 2021: $6.70B
Amgen total equity in 2021 was $6.70B.
See more financial history for Amgen (AMGN).
Sector peers by Total Equity
Healthcare peers of Amgen (AMGN), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $53.41B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- −$3.27B
Frequently asked questions
Amgen (AMGN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation